Answers are grounded in this paper and cite their sources.
Targeting the replication stress response is a valid therapeutic option to overcome PARPi resistance including tumors without an underlying HRR deficiency. These preclinical insights are now being tested in several clinical trials where the PARPi is administered with either the WEE1i or the ATRi.
No takes yet. Share an insight, caveat, or question.
Serra et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: